Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(29%)

Phase Distribution

Ph early_phase_1
1
14%
Ph not_applicable
4
57%
Ph phase_1
2
29%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
2(28.6%)
N/ANon-phased studies
4(57.1%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(2)
Terminated(3)
Other(2)

Detailed Status

Completed2
unknown2
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
50.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (14.3%)
Phase 12 (28.6%)
N/A4 (57.1%)

Trials by Status

withdrawn114%
completed229%
unknown229%
terminated229%

Recent Activity

0 active trials
Showing 5 of 7
completednot_applicable

Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma

NCT03450850
withdrawnphase_1

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

NCT04129515
completedphase_1

NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

NCT03232424
terminatednot_applicable

Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain

NCT03488472
terminatedearly_phase_1

Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas

NCT02507232
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03450850Not Applicable

Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma

Completed
NCT04129515Phase 1

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Withdrawn
NCT03232424Phase 1

NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Completed
NCT03488472Not Applicable

Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain

Terminated
NCT02507232Early Phase 1

Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas

Terminated
NCT03869242Not Applicable

NovoTTF-200A Together With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GBM

Unknown
NCT03780569Not Applicable

TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
7